Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee

BMC Musculoskeletal Disorders

Research Article

Mira Seskar¹  Melisa Cooper¹  Geetha Jonnala²  Valerie K Branch²  Nancy J Olsen³ 

[1] Phytomedics, Inc, 1085 Cranbury South River Road Suite #8, 08831, Jamesburg, NJ, USA;Rheumatic Diseases Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, 75390, Dallas, TX, USA;Rheumatic Diseases Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, 75390, Dallas, TX, USA;Division of Rheumatology, 500 University Drive, Penn State Hershey Medical Center, 17033, Hershey, PA, USA;

关键词: Chondroitin Sulfate;    Final Visit;    Brief Pain Inventory;    Hydrocodone;    Chicory Root;   

DOI  :  10.1186/1471-2474-11-156

 received in 2009-11-16, accepted in 2010-07-09,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundExtracts of chicory root have anti-inflammatory properties in vitro and in animal models of arthritis. The primary objective of this investigator-initiated, Phase 1, placebo-controlled, double blind, dose-escalating trial was to determine the safety and tolerability of a proprietary bioactive extract of chicory root in patients with osteoarthritis (OA). Secondary objectives were to assess effects on the signs and symptoms of this disorder.MethodsIndividuals greater than 50 years of age with OA of the hip or knee were eligible for trial entry. A total of 40 patients were enrolled in 3 cohorts and were treated with escalating chicory doses of 600 mg/day, 1200 mg/day and 1800 mg/day for 1 month. The ratio of active treatment to placebo was 5:3 in cohorts 1 and 2 (8 patients) each and 16:8 in cohort 3 (24 patients). Safety evaluations included measurement of vital signs and routine lab tests at baseline and the end of the treatment period. Efficacy evaluations at baseline and final visits included self-assessment questionnaires and measurement of the 25-foot walking time.ResultsIn the highest dose cohort, 18 patients who completed treatment per protocol were analyzed for efficacy. In this group, 13 patients showed at least 20% improvement in the defined response domains of pain, stiffness and global assessment: 9 of 10 (90%) patients randomized to active treatment with chicory and 4 of 8 (50%) patients randomized to placebo (P = 0.06). In general, the treatment was well-tolerated. Only one patient who was treated with the highest dose of chicory had to discontinue treatment due to an adverse event.ConclusionsThe results of this pilot study suggest that a proprietary bioactive extract of chicory root has a potential role in the management of OA and merits further investigation. Clinicaltrials.gov identifier: NCT 01010919.

【 授权许可】

CC BY   
© Olsen et al; licensee BioMed Central Ltd. 2010